Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases

Yuxin Shen†, Xiaofei Zhu†, Fei Cao†, Hongliang Xie†, Xiaoping Ju, Yangsen Cao, Shuiwang Qing, Zhen Jia, Lei Gu, Fang Fang and Huojun Zhang*

Department of Radiation Oncology, Shanghai Hospital Affiliated to Navy Medical University, Shanghai, China

Purpose/Objectives: Locally recurrent pancreatic cancer is a therapeutic challenge, and aggressive approaches are needed to improve its clinical outcomes. Stereotactic body radiotherapy (SBRT) is a promising treatment for pancreatic cancer with an excellent local control and acceptable toxicity. However, the safety and efficacy of SBRT for in-field recurrence after initial SBRT remain unknown. The aim of the study was to investigate the feasibility of re-irradiation with SBRT for locally recurrent pancreatic cancer after prior definitive SBRT.

Material/Methods: Twenty-four consecutive patients with pancreatic cancer received two courses of SBRT in our center between January 2014 and December 2016. The median prescription dose of the initial and second courses of SBRT was 35.5 Gy/5–7f and 32 Gy/5–8f, respectively. Clinical outcomes including overall survival (OS), disease control, and toxicity were evaluated after treatment.

Results: The median interval between two courses of SBRT was 13 months (range: 6–29 months). From the first SBRT, the median OS of 18 patients with limited diseases was 26 months (95% CI: 19.1–32.95 months). The median OS of 12 patients without metastasis was 14 months (95% CI: 10.6–17.4 months) from re-irradiation of SBRT. The overall response rate and disease control rate were 50% and 13%, and 100% and 86.9% after each SBRT, respectively. Carbohydrate antigen 19-9 (CA19-9) levels declined dramatically after re-irradiation within 1 month (p = 0.002) and 3 months (p = 0.028). Twelve (75%) out of 16 patients had pain relief after re-irradiation. None of the patients experienced gastrointestinal toxicity.

Conclusions: Re-irradiation with SBRT can provide favorable outcomes and effective analgesia with mild toxicity after prior SBRT for in-field recurrent pancreatic cancer, which might be feasible for locally relapsed pancreatic cancer.

Keywords: pancreatic cancer, re-irradiation, SBRT, in-field recurrence, toxicity
1 INTRODUCTION

Pancreatic cancer is one of the most lethal malignancies. The incidence and mortality have increased dramatically, and pancreatic cancer is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States by 2030 (1–3). Stereotactic body radiotherapy (SBRT) is a promising treatment for pancreatic cancer with an excellent local control and acceptable toxicity (4). However, nearly one-third of patients treated with chemoradiation have local–regional recurrence (5), and 30% of deaths are due to locally progressive disease (6). Because of the symptomatic manifestations such as pain, obstruction, portal hypertension, and malnutrition, local progression is an important factor contributing to poor prognosis and deteriorations of quality of life (7, 8). The alternative aggressive approaches for local recurrence are warranted to improve the clinical outcomes.

Re-irradiation with SBRT has been successfully applied in lung cancer, head and neck cancer, bone metastases, and other cancers (9–12). It is a promising modality in the salvage setting due to its conformality and sparing dose to critical structures around pancreatic tumor, thus reducing the risk of significant late toxicity. The previous studies have proved that re-irradiation with SBRT might be an option for patients with locoregional recurrence after conventional fractionation radiotherapy (13–17). However, few studies have investigated the feasibility of two courses of SBRT for patients with locally relapsed pancreatic cancer. To the best of our knowledge, this pilot study was the one with a large sample size to investigate the safety and efficacy of re-irradiation with SBRT for in-field recurrence after initial SBRT for pancreatic cancer.

2 MATERIALS AND METHODS

2.1 Study Population

This was a single-center retrospective study. Medical records of 24 consecutive patients treated with two courses of SBRT in our center from 2014 to 2016 were reviewed. Patients signed informed consent, and the study was approved by our institutional review board. The inclusion criteria included the following: i) patients with two courses of SBRT in our hospital, ii) in-field recurrences, iii) no involvement of the gastrointestinal tract by the tumor proven by imaging examinations and gastroscopy, iv) no upper gastrointestinal ulcer/active inflammation, and v) local recurrence confirmed by histopathological examinations or multidisciplinary approaches.

2.2 Stereotactic Body Radiotherapy Planning

The protocol of pancreatic SBRT has been described in our previous studies (18–20). SBRT was delivered by CyberKnife robotic stereotactic radiosurgery system (Accuray Inc., Sunnyvale, CA). Gross tumor volume (GTV) was delineated as a radiographically evident gross disease from both plain and contrast CT images. Clinical target volume (CTV) encompasses areas of the potential subclinical disease spread that equaled GTV. Planning target volume (PTV) was determined with 2- to 5-mm expansion from CTV. For tumors adjacent to critical organs, such as the duodenum, the expansion of PTV in this direction was reduced. Doses were prescribed to the 75%–80% isodose covering 95% of the GTV and 90% of the PTV. The radiation dose-fractionation schedule was based on the tumor size, tumor location, and the distance from organs at risk (OARs).

Regarding dose constraints of OARs, the American Association of Physicists in Medicine (AAPM) guidelines in TG-101 was referred (21). Additionally, in the case of re-irradiation with SBRT, a dose reduction of OARs was considered based on the previous study (19). Therefore, we allowed a dose reduction of 50% for a re-irradiation 12 months after the last radiation. A dose reduction of 25% was allowed for a re-irradiation 6–12 months after initial SBRT. No dose reduction was used when re-irradiation was performed within 6 months. Doses to OARs in the first SBRT would be modified according to the following conditions before summations of dose distributions of the first and second SBRTs. As a result, after completions of the treatment plans of re-irradiation, dose distributions, structures sets, and CT scans of two treatment plans were extracted from Multiplan® System (version: 4.0.2) and sent to MIM® System (version: 6.6.8) for analysis. Firstly, two CT scans were aligned rigidly via automatic bone matches (translation and rotations). Therefore, for each plan before summation, each of the contoured OARs was registered rigidly. Subsequently, a non-rigid registration was performed for projections of the dose distributions of the first plan to the second one for dose summations. The summed doses of OARs were compared with constraints. And the second plans would be modified if the summed doses exceeded the constraints. The dose constraints of OARs are listed in Table 1.

2.3 Follow-Up

The primary endpoints included overall survival (OS) and late grade 3 and higher radiation toxicity. Adverse effects induced by SBRT were evaluated by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The toxicity was evaluated every month. The secondary endpoints included local recurrence-free survival (LRFS), overall response rate (ORR), disease control rate (DCR), and numerical pain rating scale (NPRS). The OS was defined from the initial date of re-irradiation to death. The LRFS was determined from the initial date of re-irradiation to local recurrence or death. The ORR is a ratio of the number of patients with complete response (CR) plus partial response (PR) to the total number of patients eligible for evaluations. The DCR is a ratio of the number of CR, PR, plus stable disease (SD) to the total number of patients included for analysis. The definition of objective response was referred to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In-field recurrence was defined as more than
80% of the recurrence volume located in the prescription dose line.

### 2.4 Statistical Analysis

Statistical analysis was performed with SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Survival was assessed by Kaplan–Meier plots. The tests for significance were performed by the log-rank method. The difference between groups was analyzed by Wilcoxon rank sum test. A swimmer’s plot was created to depict individual disease timelines.

### 3 RESULTS

#### 3.1 Patients

Between January 2014 and December 2016, 24 consecutive patients were included. Patients’ characteristics are summarized in Table 2, and individual disease courses were depicted in a swimmer’s plot (Figure 1). Median follow-up from re-irradiation was 9 months (range, 1–41 months); and one (3.8%, No. 6) patient was lost to follow-up. Median age at the time of re-irradiation was 67 years (range, 43–84 years). The majority of patients had stage T4 disease located in the head of pancreas. Five of 24 patients (liver, Nos. 7, 14, 15, 17; and lung, No. 12) already had metastasis at initial SBRT, while another seven (liver, Nos. 4–6, 9, and 13; lung, No. 10; and peritoneum, No. 11) developed metastases along with local recurrence after initial SBRT. At time of repeat SBRT, 50% had only local disease and 50% had both local and distant metastases.

#### 3.2 Treatment Regimens

##### 3.2.1 Stereotactic Body Radiotherapy Planning and Delivery Variables

The median time between the first and second SBRTs was 13 months (range, 6–29 months). At the time of the first SBRT, the median volume of PTV was 34.8 cm³ (range, 14.8–196.1 cm³), and the median maximum diameter of GTV was 31 mm (range, 14–46 mm). The median prescription dose and biologically effective dose (BED) was 35.5 Gy/5–7f (range, 32–42 Gy) and 60.7 Gy (range, 52.5–72 Gy), respectively. Most patients (22/24) underwent 5-fraction schedule (median: 35.5 Gy, range: 32–40 Gy). The other two received 42 Gy/6f (No. 20) and 35 Gy/7f (No. 24), respectively. The median volume of PTV of re-irradiation was 18.7 cm³ (range, 10.4–139.5 cm³), and the median maximum diameter of GTV was 28 mm (range, 13–44 mm). The median prescription dose and BED of re-irradiation were 32 Gy (range, 25–40 Gy), respectively. The majority of patients (22/24) were treated in a 5-fraction schedule (median: 35.4 Gy, range: 31.8–36 Gy); and three (Nos. 17, 22, and 24) received 8 fractions (median: 29.6 Gy, range: 29–32 Gy). One (No. 23) received 35 Gy/7f.

### 3.2.2 Chemotherapy

Half of the patients received gemcitabine or 5-FU-based chemotherapy regimens for at least 6 cycles after the first SBRT. Chemotherapy was interrupted in five patients (20.1%; Nos. 3, 4, 9, 15, and 24) due to adverse effects. The remaining seven patients (29.2%; Nos. 6–8, 11, 12, 21, and 23) declined chemotherapy.
because of older age or morbidity. After re-irradiation, due to the poor physical condition or severe clinical manifestations of pancreatic cancer, 14 patients (58.3%) did not receive the chemotherapy. Only three patients (12.5%) completed six cycles of chemotherapy (doublet chemotherapy, No. 2, 10; 5-FU alone, No. 14; 5-FU and gemcitabine, No. 17) due to older age or morbidity. After re-irradiation, due to severe emphysema, received 13 and 6 cycles of doublet chemotherapy after the first and second courses of SBRT. Four months after re-irradiation, the tumor response was SD, but the CA19-9 level increased (from 23.19 to 43.14 U/ml). However, the patient himself had a strong desire to receive aggressive treatment and then received Gamma Knife at another center. Unfortunately, he hemorrhaged 7 months after radiotherapy and died of gastrointestinal fistula.

The median LRFS from the first SBRT was 13 months (95% CI: 10.7–15.3 months; Figure 2C). The rate of 6-, 12-, and 18-month LRFS was 91.3%, 52.2%, and 26.1%, respectively. After re-irradiation with SBRT, 13 patients had local progression, and 10 patients died without local progression. The median LRFS from re-irradiation was 12 months (95% CI: 7.9–16.1 months; Figure 2D). The 6- and 12-month LRFS rates were 78% and 33.4%, respectively.

### 3.4 Objective Response
The best tumor response of each patient was marked in swimmer plots (Figure 1) with differently colored triangles (details provided in Subject Status).

After the first course of SBRT, CR was found in two patients at the time of months 3 and 9. Ten patients had PR, and 12 had SD. The ORR was 50%, and the DCR was 100% after the first SBRT. After re-irradiation, three patients had PR, and three patients died without local progression. The median LRFS from re-irradiation was 12 months (95% CI: 7.9–16.1 months; Figure 2D). The 6- and 12-month LRFS rates were 78% and 33.4%, respectively.

### 3.5 Evaluation of Carbohydrate Antigen 19-9 and Pain
Considering the impact of metastasis on CA19-9, 12 patients with limited diseases at re-irradiation were included to assess CA19-9 response (Figure 4A). Compared with baseline before the first SBRT, CA19-9 level declined dramatically in 1 month (p = 0.002). Three months later, the level was lower than that at 1 month after the first SBRT (p = 0.004). After re-irradiation of SBRT, the CA19-9 level decreased significantly within 1 month (p = 0.003) and 3 months (p = 0.041).

In both courses of SBRT, cancer-induced pain was ameliorated (Figure 4B). Before the first SBRT, the median NPRS of 19 patients was 5 (range, 2–7). One month after the first SBRT, the score declined rapidly with the median score of 0 (range, 0–4, p = 0.000). Eighteen patients (94.7%) experienced alleviation of the pain during

### Table 2: Patients characteristics.

| Total no. of patients enrolled | 24 |
|--------------------------------|----|
| Gender, n                      |    |
| Male                           | 16 |
| Female                         | 8  |
| Median age, years (range)      | 65.5 (39–83) |
| Location, n                    |    |
| Head                           | 12 |
| Neck                           | 3  |
| Body                           | 9  |
| Primary tumors                 |    |
| T1c                            | 2  |
| T2                             | 7  |
| T3                             | 3  |
| T4                             | 12 |
| Regional lymph nodes           |    |
| N0                             | 9  |
| N1                             | 11 |
| N2                             | 4  |
| Metastasis                     |    |
| M0                             | 19 |
| M1                             | 5  |
| Stage                          |    |
| I IIA: 2; IIB: 2                |    |
| II IIA: 1; IIB: 1               |    |
| III                            | 13 |
| IV                             | 5  |
| KPS                            |    |
| 90                             | 6  |
| 80                             | 18 |

Note. SBRT, stereotactic body radiotherapy; KPS, Karnofsky Performance Status.

1. SBRT_1st: the first course of SBRT;
2. SBRT_2nd: the second course of SBRT.
the treatment, while 11 patients (57.9%) had complete remission at the time of completion of SBRT. Before re-irradiation of SBRT, 16 patients suffered from epigastric pain, and the median NPRS was 6 (range, 2–8). One month later, the median score decreased to 2 (range, 0–7, p = 0.000). The pain was relieved in 12 patients (75%) during the treatment, while nine patients (56.3%) reported significant remission after the second SBRT.

3.6 Toxicity
Twenty-two patients were included for evaluation of toxicity except for one patient who received Gamma Knife in another center for the same lesion after re-irradiation.

No patients experienced grade 4 or 5 toxicity. No one suffered from late gastrointestinal toxicity. One patient developed acute grade 3 vomiting and diarrhea after re-irradiation and recovered after hospitalization. Grade 2 nausea and emesis were found in one patient after the first SBRT. Additionally, five patients had acute grade 2 toxicity after re-irradiation (nausea, 3; vomiting, 1; anergy, 2; diarrhea, 2; myelosuppression, 2).

4 DISCUSSION
Given local progression after initial aggressive treatment, management of pancreatic cancer becomes more challenging. There were limited treatment options for patients with locally relapsed pancreatic cancer after aggressive multimodality, and no consensus has been reached on the optimal treatment strategy. These patients are usually non-surgical candidates due to factors such as age, comorbidities, performance status, or advanced tumor stage with vascular involvement or post-radiation fibrosis. In studies evaluating different alternatives for isolated local recurrence of pancreatic cancer after various regimens, median survival was reported with 32, 19, and 16 months for re-resection, chemoradiotherapy, and SBRT, respectively (22). However, because patients with different stages were included, the optimal treatment still remained controversial. Each of these options has its own drawbacks, for instance, the invasiveness and morbidity with re-resection; poor response rates, systemic toxicity, and modest local control with palliative chemotheray (23, 24); significant morbidity such as pain and obstruction with radiotherapy (25); and lack of efficacy with supportive care alone. It is believed that these patients are most likely to benefit from intensive local therapy.

SBRT provides a high local control and potential survival benefits for pancreatic cancer. Till now, only five retrospective studies reported prognosis and toxicity of SBRT as treatment options for patients with recurrent pancreatic cancer who had received prior radiotherapy (including conventional fractionation radiotherapy and SBRT). In Table 3, we have summarized the published five studies with different focus. Conventional fractionation radiotherapy was commonly applied as the initial treatment. Only 10 patients reported by Dagoglu et al. (15)
received two courses of SBRT, whereas detailed patients’ characteristics and outcomes were not disclosed. The median OS of patients with limited diseases from re-irradiation in our study was 14 months and was comparable with that reported by Dagoglu et al. However, half of the included patients in the study had stage I and II, while 75% (9/12) of patients in our study had stage III. In the remaining four published studies (13, 14, 16, 17), the median OS with limited diseases was 6–9 months after re-irradiation with SBRT. Hence, our study showed superior survival rate compared with that in previous studies, which might be attributable to the two courses of SBRT and higher prescription dose for these patients.

The median prescription dose and fractionation adopted in our study were higher than in the previous studies (13–16), which might be associated with a satisfactory local control rate and a very low toxicity profile. No patients had late adverse events after re-irradiation in this study, and the incidence was much lower than that in the previous investigations (13–15, 17). None of the patients experienced small intestine obstruction and duodenal stenosis. This might be attributed to the use of SBRT as initial treatment and the 5–8 fractions used in re-irradiation. Koong et al. (16) reported that 26.1% of patients developed grade 2 or 3 gastrointestinal toxicity, two-thirds of whom received a single-fraction SBRT regimen. Lominska et al. (13) and Sutera et al. (17) showed that the late gastrointestinal toxicity above grade 3 often occurred in patients who underwent 1–3 fractions. Therefore, it was suggested that a multi-fraction SBRT regimen may result in less toxicity. The fractionation schedule in our study comprised of 5–8 fractions, which might contribute to the better tolerance. Koong et al. (16) have specified for the adequate time for allowing normal tissues to repair before the delivery of a new course of radiation treatment, particularly when using hypofractionation. This was in line with our study with the

![FIGURE 2](image-url) (A) Overall survival of patients with or without distant metastasis from the first SBRT. (B) Overall survival of patients with various stages from re-irradiation with SBRT. (C) LRFS of 23 patients from the first SBRT. (D) LRFS of 23 patients from re-irradiation with SBRT. SBRT, stereotactic body radiotherapy; LRFS, local recurrence-free survival.
The median interval of 13 months (range, 6–29 months) between the first and second SBRTs, which led to the low incidence of adverse effects in our study.

CA19-9 is considered as one of the most useful biomarkers for the assessment of pancreatic cancer (26). Our previous studies (20) developed a predictive model for stratification of patients with pancreatic cancer who may achieve survival benefits from re-irradiation with SBRT. Multivariable analysis showed that tumor stage, BED10, and CA19-9 response were significantly predictive of OS, which formed the components of Stage, CA19-9 response, BED10 (SCAD) scoring system. Our study was the only one evaluating CA19-9 levels in this setting. It was observed that CA19-9 levels declined significantly within 1 month (p = 0.002) and 3 months (p = 0.028), compared with those prior re-irradiation with SBRT.

Approximately 70% of patients suffered pain at the time of diagnosis (27). The significant pain relief was observed soon after SBRT in most patients, including patients with distant metastasis. There was a 4-point reduction in median NPRS after re-irradiation of SBRT in 16 patients who experienced epigastric pain. Similarly, pain was also alleviated in 75% of patients during the treatment, and 56.3% of patients reported significant remission after the second SBRT. Hence, we inferred that SBRT was a better option for analgesia.

In terms of RECIST response rates, the percentage of ORR and DCR was 50% and 100% after the first SBRT and 13% and 86.9% after re-irradiation, which may indicate that the purpose of re-irradiation was disease and pain control. However, three patients with distant metastasis died within 3 months after re-irradiation. Therefore, although re-irradiation with SBRT may contribute to effective analgesia for patients with metastatic pancreatic cancer, careful pretreatment evaluations were required for selection of patients who were indicated for re-irradiation with SBRT.

The results of this study should be interpreted within the context of its limitations, including being a single-center study, having a retrospective nature, non-randomization, and a small sample size. In spite of the limitations, the study had strengths that should be acknowledged. To our knowledge, this is the first study that integrated the pain parameters and CA19-9, which need to be correlated with other investigations for better clinical judgement.
5 CONCLUSIONS

Re-irradiation with SBRT is a feasible strategy for in-field recurrence of pancreatic cancer after prior SBRT, with favorable OS rate and acceptable treatment-related toxicity, especially in patients with no distant metastases. Pain remission should be considered for selected patients with metastatic pancreatic cancer if a second SBRT was performed. Two courses of SBRT, a higher dose of re-irradiation, and multi-fraction schemes might result in favorable local control and survival with acceptable toxicity.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the articlesupplementary material. Further inquiries can be directed to the corresponding author.
ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

YS, XZ, FC, and HX designed the experiments and wrote the paper. YC helped to analyze the treatment planning. HZ revised the paper. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
2. Misrahi JD, Surana R, Valie JW, Shroff RT. Pancreatic Cancer. Lancet (2020) 395(10242):2008–20. doi: 10.1016/S0140-6736(20)30974-0
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM, et al. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res (2014) 74:2993–21. doi: 10.1158/0008-5472.CAN-14-0155
4. Goldsmith C, Plowman PN, Green MM, Dale RG, Price PM. Stereotactic Ablative Radiotherapy (SABR) as Primary, Adjuvant, Consolidation and Re-Treatment Option in Pancreatic Cancer: Scope for Dose Escalation and Lessons for Toxicity. Radiat Oncol (2018) 13(1):204. doi: 10.1186/s13014-018-1138-3
5. Hammel P, Huguet F, van Laethem JL. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA (2016) 315:1844–53. doi: 10.1001/jama.2016.4324
6. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. J Clin Oncol (2009) 27:1806–13. doi: 10.1200/JCO.2008.17.7188
7. Rudra S, Narang AK, Pawlik TM, Wang H, Jaffe EM, Zheng L, et al. Evaluation of Predictive Variables in Locally Advanced Pancreatic Adenocarcinoma Patients Receiving Definitive Chemoradiation. Pract Radiat Oncol (2012) 2:77–85. doi: 10.1016/j.prro.2011.06.009
8. Ogawa K, Shibuya H, Uchida N, Onishi H, Okuno Y, Miyojin M, et al. Postoperative External Beam Radiotherapy for Resected Pancreatic Adenocarcinoma: Impact of Chemotherapy on Local Control and Survival. Anticancer Res (2010) 30:2959–67.
9. Valakha V, Miyamoto C, Micaiby B, Chan P, Neicu T, Li S, et al. Repeat Stereotactic Body Radiation Therapy for Patients With Pulmonary Malignancies Who had Previously Received SBRT to the Same or an Adjacent Tumor Site. J Cancer Res Ther (2013) 9(4):680–5. doi: 10.4103/0973-1482.126481
10. Heron DE, Ferris RL, Karamouzis M, Andrade RS, Burton S, et al. Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial. Int J Radiat Oncol Biol Phys (2009) 75(5):1493–500. doi: 10.1016/j.ijrobp.2008.12.075
11. Lartigau EF, Tresch E, Thariat J, Graff P, Coche-Dequeant B, Benezery K, et al. The Multi Institutional Phase II Study of Concomitant Stereotactic Reirradiation and Cetuximab for Recurrent Head and Neck Cancer. Radiother Oncol (2013) 109(2):281–5. doi: 10.1016/j.radonc.2013.08.012
12. Mahadevan A, Floyd S, Wong E, Jeyapalan S, Groff M, Kasper, et al. Stereotactic Body Radiotherapy Reirradiation for Recurrent Epidermal Spinal Metastases. Int J Radiat Oncol Biol Phys (2011) 81(5):1500–5. doi: 10.1016/j.ijrobp.2010.08.012
13. Lominska CE, Unger K, Nasr NM, Haddad N, Gagnon G. Stereotactic Body Radiation Therapy for Reirradiation of Localized Adenocarcinoma of the Pancreas. Radiat Oncol (2012) 7:74. doi: 10.1186/1748-717X-7-74
14. Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, et al. Re-Irradiation With Stereotactic Body Radiation Therapy as a Novel Treatment Option for Isolated Local Recurrence of Pancreatic Cancer After Multimodality Therapy: Experience From Two Institutions. J Gastrointest Oncol (2013) 4:43–51. doi: 10.3978/j.issn.2078-6891.2013.004
15. Dagognon N, Callery M, Moser J, Tseng J, Kent T, Bullock A, et al. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer (2016) 73(3):283–8. doi: 10.1759/ijca13925
16. Koong AJ, Toesca DAS, von Eyben R, Polom EL, Chang DT. Reirradiation With Stereotactic Body Radiation Therapy After Prior Conventional Fractionation Radiation for Locally Recurrent Pancreatic Adenocarcinoma. Adv Radiat Oncol (2017) 2(1):27–36. doi: 10.1016/j.adro.2017.01.003
17. Sutera P, Bernard ME, Wang H, Bahary N, Burton S, Zeh H, et al. Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer After Prior Radiation. Front Oncol (2018) 8:52. doi: 10.3389/fonc.2018.00052
18. Zhu X, Ju X, Cao Y, Shen YX, Cao F, Qing SW, et al. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Targeted Volume Design. Int J Radiat Oncol Biol Phys (2019) 104:101–10. doi: 10.1016/j.ijrobp.2019.01.075
19. Zhu X, Li P, Ju X, Shen YX, Cao YS, Cao F, et al. Prediction of Overall Survival After Re-Irradiation With Stereotactic Body Radiation Therapy for Pancreatic Cancer With a Novel Prognostic Model (the SCAD Score). Radiat Oncol (2018) 12(2):315–8. doi: 10.1186/s13014-2018-08012
20. Zhu X, Li P, Liu W, Shi DC, Ju XP, Cao YS, et al. Stereotactic Body Radiation Therapy Plus Induction or Adjuvant Chemotherapy for Early Stage But Medically Inoperable Pancreatic Cancer: A Propensity Score-Matched Analysis of a Prospectively Collected Database. Cancer Manag Res (2018) 10:1295–304. doi: 10.2147/cmrr.s163655
21. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic Body Radiation Therapy: The Report of AAPM Task Group 101. Med Phys (2010) 37:4078–101. doi: 10.1118/1.3438081
22. Groot VP, van Santvoort HC, Hageman J, Borel Rinkes IHM, van Vulpen M, et al. Systematic Review on the Treatment of Isolated Local Recurrence of Pancreatic Cancer After Surgery: Re-Resection, Chemoradiotherapy and SBRT. HPB (Oxford) (2017) 19(2):83–92. doi: 10.1111/hpb.2016.11.001
23. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreatic Cancer: A Randomized Trial. J Clin Oncol (1997) 15(6):2403–10. doi: 10.1200/JCO.1997.15.6.2403
24. Lee MG, Lee SH, Lee SJ, Hwang JH, Ryu JK, et al. 5-Fluorouracil/ Leucovorin Combined With Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients With Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy. Chemotherapy (2013) 59(4):273–9. doi: 10.1159/000356158
25. Myrehaug S, Sahgal A, Russo SM, Lo SS, Rosati LM, Mayr NA, et al. Stereotactic Body Radiotherapy for Pancreatic Cancer: Recent Progress and

FUNDING

This study was sponsored by grants from the Special Project of Ministry of Science and Technology (2017YFC0113104) and the National Natural Science Foundation of China (Grant No. 81803168).

ACKNOWLEDGMENTS

We appreciated Dr. Jiuhong Chen for her precise comments.
Future Directions. Expert Rev Anticancer Ther (2016) 16:523–30. doi: 10.1586/14737140.2016.1168698

26. Ballehaninna UK, Chamberlain RS. The Clinical Utility of Serum CA19–9 in the Diagnosis, Prognosis and Management of Pancreatic Adenocarcinoma: An Evidence Based Appraisal. J Gastrointest Oncol (2012) 3:105–19. doi: 10.3978/j.issn.2078-6891.2011.021

27. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in Primary Care: A Systematic Review. Pancreas (2016) 45:814–18. doi: 10.1097/MPA.0000000000000527

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shen, Zhu, Cao, Xie, Ju, Cao, Qing, Jia, Gu, Fang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.